The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

A local pharmacist is bringing together federal and state leaders to explain why drug prices are so high and what needs to be done to change that.

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

Global Hemostasis Products MarketThe global hemostasis products market is poised for substantial growth, with an estimated valuation of USD 1.58 billion in 2023 and projected to exceed USD 2.65 ...

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...

Columnist Alliah Czarielle clears up some common misconceptions about what happens when people with hemophilia have minor cuts or abrasions.

Burke is one of a growing number of adults who suspect they might have undiagnosed ADHD. About 25% of adults think they have ...

Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.

Some Keller students and parents are pushing back against a new district practice that they say amounts to censorship of ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...